MCID: HDG003
MIFTS: 27

Hodgkin's Lymphoma, Lymphocytic Depletion

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Hodgkin's Lymphoma, Lymphocytic Depletion

MalaCards integrated aliases for Hodgkin's Lymphoma, Lymphocytic Depletion:

Name: Hodgkin's Lymphoma, Lymphocytic Depletion 12 15
Hodgkin's Lymphocytic Depletion of Unspecified Site 12
Classic Hodgkin Lymphoma, Lymphocyte-Depleted Type 58
Lymphocyte-Depleted Classical Hodgkin Lymphoma 12
Hodgkin's Disease, Lymphocytic Depletion 12
Hodgkin Lymphoma, Lymphocyte Depletion 12

Characteristics:

Orphanet epidemiological data:

58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:8628
ICD9CM 34 201.7
MeSH 44 D006689
NCIt 50 C9283
SNOMED-CT 67 112687003
ICD10 32 C81.3
ICD10 via Orphanet 33 C81.3
UMLS via Orphanet 71 C0152267
Orphanet 58 ORPHA98846
UMLS 70 C0152267

Summaries for Hodgkin's Lymphoma, Lymphocytic Depletion

MalaCards based summary : Hodgkin's Lymphoma, Lymphocytic Depletion, also known as hodgkin's lymphocytic depletion of unspecified site, is related to lymphoma, hodgkin, classic and marginal zone b-cell lymphoma. An important gene associated with Hodgkin's Lymphoma, Lymphocytic Depletion is POU2AF1 (POU Class 2 Homeobox Associating Factor 1), and among its related pathways/superpathways is NF-kappaB Signaling. The drugs Dexamethasone and Cisplatin have been mentioned in the context of this disorder. Related phenotypes are hematopoietic system and immune system

Related Diseases for Hodgkin's Lymphoma, Lymphocytic Depletion

Diseases related to Hodgkin's Lymphoma, Lymphocytic Depletion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 30.8 TNFRSF8 POU2AF1 PAX5
2 marginal zone b-cell lymphoma 29.7 TNFRSF8 PAX5 CD79A
3 myelofibrosis 10.2
4 lymphoma 10.2
5 splenomegaly 10.2
6 spherocytosis, type 4 10.0 POU2AF1 PAX5
7 primary cutaneous b-cell lymphoma 10.0 POU2F2 PAX5
8 submandibular adenitis 10.0 TNFRSF8 PAX5
9 breast lipoma 10.0 TNFRSF8 PAX5
10 tracheal lymphoma 10.0 TNFRSF8 PAX5
11 hodgkin's lymphoma, mixed cellularity 10.0 TNFRSF8 FUT4
12 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.0 TNFRSF8 FUT4
13 pleural lipoma 10.0 TNFRSF8 FUT4
14 t-cell/histiocyte rich large b cell lymphoma 10.0 TNFRSF8 POU2F2
15 uterus leiomyosarcoma 9.9 TNFRSF8 FUT4
16 uterine corpus sarcoma 9.9 TNFRSF8 FUT4
17 reticulosarcoma 9.9 TNFRSF8 PAX5
18 adult acute lymphocytic leukemia 9.9 TNFRSF8 PAX5
19 monoclonal paraproteinemia 9.9 PAX5 CD79A
20 lymphoblastic lymphoma 9.8 TNFRSF8 PAX5
21 spleen cancer 9.8 PAX5 CD79A
22 cll/sll 9.8 PAX5 CD79A
23 lymphoplasmacytic lymphoma 9.8 PAX5 CD79A
24 myeloid sarcoma 9.8 PAX5 CD79A
25 infected hydrocele 9.8 TNFRSF8 CD79A
26 bone lymphoma 9.8 TNFRSF8 CD79A
27 breast lymphoma 9.8 TNFRSF8 CD79A
28 cerebral lymphoma 9.8 TNFRSF8 CD79A
29 gastrointestinal lymphoma 9.8 TNFRSF8 CD79A
30 pediatric lymphoma 9.8 TNFRSF8 CD79A
31 testicular lymphoma 9.8 TNFRSF8 CD79A
32 membranoproliferative glomerulonephritis 9.7 FUT4 CD79A
33 b-cell lymphoma 9.7 TNFRSF8 POU2F2 PAX5
34 anaplastic large cell lymphoma 9.7 TNFRSF8 PAX5
35 plasmacytoma 9.7 PAX5 CD79A
36 mature t-cell and nk-cell lymphoma 9.7 TNFRSF8 CD79A
37 paranasal sinus lymphoma 9.6 TNFRSF8 PAX5 CD79A
38 lung lymphoma 9.6 TNFRSF8 PAX5 CD79A
39 pleural empyema 9.6 TNFRSF8 PAX5 CD79A
40 multicentric castleman disease 9.6 TNFRSF8 PAX5 CD79A
41 central nervous system hematologic cancer 9.6 TNFRSF8 PAX5 CD79A
42 mature b-cell neoplasm 9.6 TNFRSF8 PAX5 CD79A
43 lymphoma, mucosa-associated lymphoid type 9.6 TNFRSF8 PAX5 CD79A
44 common variable immunodeficiency 9.5 TNFRSF8 POU2AF1 CD79A
45 diffuse large b-cell lymphoma 9.5 TNFRSF8 PAX5 CD79A
46 lymphoma, non-hodgkin, familial 9.4 TNFRSF8 PAX5 CD79A
47 leukemia, chronic lymphocytic 9.3 TNFRSF8 PAX5 CD79A
48 hodgkin's lymphoma, nodular sclerosis 9.3 TNFRSF8 PAX5 FUT4 CD79A
49 composite lymphoma 9.3 TNFRSF8 PAX5 FUT4 CD79A
50 mediastinal cancer 9.3 TNFRSF8 PAX5 FUT4 CD79A

Graphical network of the top 20 diseases related to Hodgkin's Lymphoma, Lymphocytic Depletion:



Diseases related to Hodgkin's Lymphoma, Lymphocytic Depletion

Symptoms & Phenotypes for Hodgkin's Lymphoma, Lymphocytic Depletion

MGI Mouse Phenotypes related to Hodgkin's Lymphoma, Lymphocytic Depletion:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.43 CD79A FUT4 PAX5 POU2AF1 POU2F2 TNFRSF8
2 immune system MP:0005387 9.1 CD79A FUT4 PAX5 POU2AF1 POU2F2 TNFRSF8

Drugs & Therapeutics for Hodgkin's Lymphoma, Lymphocytic Depletion

Drugs for Hodgkin's Lymphoma, Lymphocytic Depletion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
2
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
4
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
5
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
6
Etoposide Approved Phase 3 33419-42-0 36462
7
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
8
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Ichthammol Approved Phase 3 8029-68-3
11
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
12
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
13
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
14
Cortisone Experimental Phase 3 53-06-5 222786
15 Tubulin Modulators Phase 3
16
protease inhibitors Phase 3
17 Antibiotics, Antitubercular Phase 3
18 Etoposide phosphate Phase 3
19 Alkylating Agents Phase 3
20 Gastrointestinal Agents Phase 3
21
Liposomal doxorubicin Phase 3 31703
22 Ophthalmic Solutions Phase 3
23 Anti-Infective Agents Phase 3
24 Antiemetics Phase 3
25 Immunosuppressive Agents Phase 3
26 Adjuvants, Immunologic Phase 3
27 Antirheumatic Agents Phase 3
28 Hormones Phase 3
29 Hormone Antagonists Phase 3
30 Keratolytic Agents Phase 3
31 glucocorticoids Phase 3
32 Antimitotic Agents Phase 3
33 Antineoplastic Agents, Hormonal Phase 3
34 Pharmaceutical Solutions Phase 3
35 BB 1101 Phase 3
36 Dermatologic Agents Phase 3
37 Antimetabolites Phase 3
38 Podophyllotoxin Phase 3 518-28-5
39 HIV Protease Inhibitors Phase 3
40 Anti-Inflammatory Agents Phase 3
41 Antiviral Agents Phase 3
42 Anti-Bacterial Agents Phase 3
43 Immunologic Factors Phase 1
44 Immunoglobulins Phase 1
45 Antibodies Phase 1
46 Antibodies, Monoclonal Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease Completed NCT00025259 Phase 3 Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
2 Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520 by Advanced Tumor Subjects Recruiting NCT03657381 Phase 1 Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection

Search NIH Clinical Center for Hodgkin's Lymphoma, Lymphocytic Depletion

Genetic Tests for Hodgkin's Lymphoma, Lymphocytic Depletion

Anatomical Context for Hodgkin's Lymphoma, Lymphocytic Depletion

Publications for Hodgkin's Lymphoma, Lymphocytic Depletion

Articles related to Hodgkin's Lymphoma, Lymphocytic Depletion:

# Title Authors PMID Year
1
Abdominal Lymphocyte-Depleted Hodgkin Lymphoma: A Rare Presentation. 61
31807052 2019
2
Lymphocyte-depleted classical Hodgkin lymphoma accompanied by myelofibrosis. 61
28781273 2017
3
EBV-related primary splenic lymphocyte-depleted classical Hodgkin lymphoma. 61
26193900 2015
4
Lymphocyte depleted Hodgkin lymphoma: an evaluation with immunophenotyping and genetic analysis. 61
19455461 2009

Variations for Hodgkin's Lymphoma, Lymphocytic Depletion

Expression for Hodgkin's Lymphoma, Lymphocytic Depletion

Search GEO for disease gene expression data for Hodgkin's Lymphoma, Lymphocytic Depletion.

Pathways for Hodgkin's Lymphoma, Lymphocytic Depletion

Pathways related to Hodgkin's Lymphoma, Lymphocytic Depletion according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.31 TNFRSF8 PAX5 CD79A

GO Terms for Hodgkin's Lymphoma, Lymphocytic Depletion

Biological processes related to Hodgkin's Lymphoma, Lymphocytic Depletion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of interleukin-6 production GO:0032755 9.16 POU2F2 POU2AF1
2 cellular response to virus GO:0098586 8.96 POU2F2 POU2AF1
3 humoral immune response GO:0006959 8.8 POU2F2 POU2AF1 PAX5

Sources for Hodgkin's Lymphoma, Lymphocytic Depletion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....